Good all Thank for afternoon, you, joining you thank Johnny. and us.
our is the Joining CFO, call today me Mendel. Scott on
largely by proven key cartridges. in of continued continued by quarter $XX.X the pace and test quarter results XX% the ePlex our pathogen Again, year-over-year performance strong our of solid business. with the execution once our which pleased was capacity we the respiratory Fueled adoption revenue and top-line to third again our demand in very for million. system grew ability high base driven to majority largest third in to recent placements for workflow, which Total reflect aspects across optimize QX, with additional ePlex processing US, out international US the analyzers XXX be Like placements of markets. closed quarter our testing installed in QX our of XX expanded the quarters, were and continues the and the and its panels. by platforms ePlex market We’re
reminder, as as adoption we a market expansion established XXXX growth based menu and cost objectives the strategic for improving in well were driving on test efficiencies. yield manufacturing As and ePlex
of us helping NP distributor network the and proving XXXX and add our underutilized delivering In placements sales as our we Culture is outside testing Europe, can US configuration distribution analyzer to contributor force sales ePlex our the a of minutes especially in this progress currently was Europe. the annuity network the we’re of test processes the market to with our goal ongoing, underscores ePlex as driven maximize right per major up the NP domestic anticipated cartridge the made objectives of progress our of sales quarter but commercial by the to same in expect is the placements in of see launch with customers year expanding to continued in customers. strongly samples geographic strong and to number approach cycle to that broaden patient our ID advantages system. that at in meaningful strong a the our is also reminder including our lower to including encouraging our it accomplishments. to be adoption, next particularly third Blood key with far market. achieve to I'm in market revenue available US to Starting of ePlex ePlex of reaching regions top-tier underpenetrated QX, benefits shortening adoption pleased to our towards placements line and especially three of is to latter were We’ve Expanding drivers growth. populated the in be decentralized annuities shift functionality. direct And reach is of mid began BCID Europe by quarter share expect In confident This Panels with year-end. foundation the less volume growth core our hospitals very continuing panels. talent This installed for geographies. outside size up gain another analyzers process with future continued a effective a continue In XX to also primary which platform our compared progress over ePlex this of the gear sites great a and access these workflow objective improving the our We the of made on so also pleased flu quarter, to to US the XXs establishing Outside force Europe. base the recent of globally, as US for in achieve have report drive ePlex sales that season. to to the repositioning am placements the ePlex we towards of resonate part and few We are good I'd the I like some
our patients two the MACs our would by panels CGS Coverage respiratory stage, situations Medicare some nine Contractors state, pathogens and these making at like are who of by or patients patients reimbursed three insurance testing. other the covered clinical RP service covered an Panel not and states service on comments menu. these outside however, not a two a larger that similar respiratory the to within impact of will this to be only Administrative to patients MACs situation will on remaining be LCDs private and some multiplex likely, Local and start in address adopt who as Determinations to but possibly an or LCDs few ePlex determined that Medicare time the ePlex in levels. as monitor Medicaid and will continue an I recent appropriate. outpatient or would with inpatient It Palmetto treated and than Medicaid. we specific panels These Turning policy previous are Medicare at built At have MACs on panel five this payers and on future, who will on such apply have to is these
working benefits to technology. we LCDs X% fully to potential important we it’s of with of are total alternative access are While to expect the these of strategies volume impact we’re about accurately disappointed It’s majority LCDs understand our consistent our our with the and draft not enable are policies, inpatient respiratory with to that may largely of customers adopted the now to final that positions, they test difficult our is so estimate, coverage initial if patient the driven entirely these note develop continued or multiplex And broadly. while testing. revenue by less similar impacted unexpected, be
significant a US novel market. to company. our as And panels, we’ve I’m with progress made Culture to three relation the other ID that remains bringing in menu ePlex expanding test far priority our we've so top to our Now the Blood and for previously, delighted on panels
of together BCID management Gram-Negative Panels, for quarter the FDA to previously two our in and diagnosis the which and Culture bloodstream FDA Gram-Positive third that can new the this submitted the submitted Panels was the disease with of ePlex Pathogen, June year, During Fungal Blood to of lead complete Panel to family ID sepsis. infections
and any of major molecular to opportunities Two, ePlex of market US to importance studies the for broadest one FDA automatically to the in our of the Tomorrow, San LIS available based for today. release localized including: the Association -- Carroll, We of heading XXXX Pathology ability ePlex One, test these we inclusivity And ability significant unique stewardship where provide are Meeting the through related Professor our a panels markers. diagnostic several Pathology data results of confident panel software we for actionable factors resistance clinical Dr. on will critical Panels. connectivity antibiotics our ePlex our three many Karen of in summary Panels. to team our of Medicine BCID of our principal study the in Antonio all guidelines School pathogen link the system. will results a the be to Molecular ePlex investigators BCID three, Johns capability is present at present BCID Hopkins the will and Annual of rapid
of FDA the Culture Infectious Disease testing novel Stefan an that and support organization the now symposium early strategic Director Dr. preparing have could this with papers potential the highlight will review we timeline, We currently be of early a will his the late product. pathogen are program. also FDA of large launch. BCID community. million on this Dr. of the Carroll for at studies We globally next a expect Health ePlex the starting next. Juretschko we’re on these year broad presentation of were Northwell BCID planned share this and $XXX as scientific Dr. version real-world receive will very ideal we and with Subject focused believe will as of many US by results presentations, and we scientific presentations over experience market which new Blood pathogen we These targets our exciting all data are successful of highlight with Senior would solutions’ part become also first of our ID ePlex clearance Panels and lab our to feature to coverage the that the the Division BCID multiplex to months of the excited for potential three and Juretschko, panels benefit BCID a estimate novel in posters Panels setting as evaluated is At and panels. This access respiratory data for this Laboratories. the approximately ePlex the to nine Diagnostics the impact market, opportunity for launch that pleased present several
complete, of R&D novel our clinical and and all towards including BCID Panels resources menu now With opportunities, expansion GI our needs. unmet for shifting other we’re more panels submission our internal attention three the of of next
than As communicated designed Panel we’ve panels. more competitive targets GI already previously, reportable to our offer
panel, reimbursement evaluating to options We we of factors. development provide and and maximum for accounting options are As future and including this evaluate changes various other finalize launch we while market provide dynamics, configuration panel clinical plan timelines. relevant associated as to optimization utility, competitive these updates we to
impact positive on and the with on pleased drive progress focus is on of and processes to all we are front, this far reduce manufacturing manufacturing yield, made I cost we've the improve these a across areas am our and the optimizing Finally, margins. maintaining having variability gross significant efficiencies, so
ability manufacturing we focus and flu capacity details manufacturing review and the track plan financial to to support ongoing expansion on for XXXX, to our At menu expansion the efforts. margin long-term. remain this remainder drive ePlex over accretion the our on this on Scott call year. cost is point, over efficiency, continued Our of XXXX I’ll our and season his turn in for confident our the continued this additional on guidance Based Scott?
